Rodríguez Daniel, Gurevich Ekaterina, Mohammadi Jouabadi Soroush, Pastor Arroyo Eva Maria, Ritter Alexander, Estoppey Younes Sandrine, Wagner Carsten A, Imenez Silva Pedro Henrique, Seeger Harald, Mohebbi Nilufar
Division of Nephrology, University Hospital Zurich, Zurich, Switzerland.
Department of Internal Medicine , Division of Vascular Medicine and Pharmacology, Erasmus Medical Center, University Medical Center Rotterdam, the Netherlands.
Clin Kidney J. 2023 Nov 1;17(1):sfad256. doi: 10.1093/ckj/sfad256. eCollection 2024 Jan.
Kidney stones are frequent in industrialized countries with a lifetime risk of 10 to 15%. A high percentage of individuals experience recurrence. Calcium-containing stones account for more than 80% of kidney stones. Diet, environmental factors, behavior, and genetic variants contribute to the development of kidney stones. Osteocytes excrete the 21 kDa glycoprotein sclerostin, which inhibits bone formation by osteoblasts. Animal data suggests that sclerostin might directly or indirectly regulate calcium excretion via the kidney. As hypercalciuria is one of the most relevant risk factors for kidney stones, sclerostin might possess pathogenic relevance in nephrolithiasis.
We performed a prospective cross-sectional observational controlled study in 150 recurrent kidney stone formers (rKSF) to analyse the association of sclerostin with known stone risk factors and important modulators of calcium-phosphate metabolism. Serum sclerostin levels were determined at the first visit. As controls, we used 388 non-stone formers from a large Swiss epidemiological cohort.
Sclerostin was mildly increased in rKSF in comparison to controls. This finding was more pronounced in women compared to men. Logistic regression indicated an association of serum sclerostin with rKSF status. In hypercalciuric individuals, sclerostin levels were not different from normocalciuric patients. In Spearman correlation analysis we found a positive correlation between sclerostin, age, and BMI and a negative correlation with eGFR. There was a weak correlation with iPTH and intact FGF 23. In contrast, serum sclerostin levels were not associated with 25-OH Vitamin D3, 1,25-dihydroxy-Vitamin D3, urinary calcium and phosphate or other urinary lithogenic risk factors.
This is the first prospective controlled study investigating serum sclerostin in rKSF. Sclerostin levels were increased in rKSF independent of hypercalciuria and significantly associated with the status as rKSF. It appears that mechanisms other than hypercalciuria may be involved and thus further studies are required to elucidate underlying pathways.
肾结石在工业化国家很常见,终生患病风险为10%至15%。很大一部分患者会复发。含钙结石占肾结石的80%以上。饮食、环境因素、行为和基因变异都与肾结石的形成有关。骨细胞分泌21 kDa糖蛋白硬化蛋白,它可抑制成骨细胞的骨形成。动物数据表明,硬化蛋白可能直接或间接通过肾脏调节钙排泄。由于高钙尿症是肾结石最相关的危险因素之一,硬化蛋白可能在肾结石病中具有致病相关性。
我们对150例复发性肾结石患者(rKSF)进行了一项前瞻性横断面观察对照研究,以分析硬化蛋白与已知结石危险因素及钙磷代谢重要调节因子之间的关联。在首次就诊时测定血清硬化蛋白水平。作为对照,我们使用了来自瑞士一个大型流行病学队列的388例无结石患者。
与对照组相比,rKSF患者的硬化蛋白水平略有升高。这一发现在女性中比男性更为明显。逻辑回归表明血清硬化蛋白与rKSF状态有关。在高钙尿症患者中,硬化蛋白水平与正常钙尿症患者无异。在Spearman相关性分析中,我们发现硬化蛋白与年龄、BMI呈正相关,与估算肾小球滤过率(eGFR)呈负相关。与甲状旁腺激素(iPTH)和完整成纤维细胞生长因子23(FGF 23)的相关性较弱。相比之下,血清硬化蛋白水平与25-羟基维生素D3、1,25-二羟基维生素D3、尿钙和磷或其他尿结石形成危险因素无关。
这是第一项研究rKSF患者血清硬化蛋白的前瞻性对照研究。rKSF患者的硬化蛋白水平升高,与高钙尿症无关,且与rKSF状态显著相关。似乎可能涉及高钙尿症以外的机制,因此需要进一步研究以阐明潜在途径。